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Effects of fluorocitrate on renal ammoniagenesis and glutamine
metabolism in the intact dog kidney. Renal glutamine metabolism
was studied in vivo following infusions of fluorocitrate into
chronically acidotic and aikalotic dogs. Coincident with a dra-
matic rise in renal cortical citrate concentrations, there was a
significant fall in tissue glutamate in both acid-base states. This
was accompanied by a significant increase in total renal ammonia
production. Glutamine metabolism and ammoniagenesis in alka-
lotic dogs receiving fluorocitrate simulated that achieved in aci-
dotic dogs. The simultaneous administration of cs-ketogiutarate
and fluorocitrate significantly diminished the fall in tissue gluta-
mate and the rise in ammoniagenesis induced by fluorocitrate
alone. These results are compatible with the hypothesis that am-
monia production from glutamine is enhanced secondary to in-
creased glutamate deamination. We postulate that this chain of
events may be the consequence of impaired cs-ketoglutarate pro-
duction from citrate.
Effets du fluorocitrate sur l'ammoniogenese rénale et le métabo-
lisme de Ia glutamine dans le rein de chien. Le métabolisme renal
de Ia glutamine a été étudié in vivo après perfusion de fluorocit-
rate a des chiens en acidose et en alcalose. En méme temps
qu'une augmentation considerable des concentrations corticales
de citrate ii a ëté observe une diminution significative du contenu
tissulaire en glutamate dans les deux états acido-basiques étu-
dies. Cela a Cté accompagne d'une augmentation significative de
Ia production rénale totale d'ammoniaque. Le métabolisme de la
glutamine et l'ammoniogénese chez des chiens en aicalose rece-
vant du fluorocitrate est semblable ?t celui des chiens en acidose.
L'administration simultanée d'aipha-cetoglutarate et de fluoro-
citrate diminue significativement Ia chute du glutamate tissulaire
et laugmentation de l'ammoniogénêse déterminëes par le
fluorocitrate seul. Ces résultats sont compatibles avec
l'hypothèse scion laquelle Ia production d'ammoniaque a partir
de Ia glutamine est accrue secondairement a i'augmentation de Ia
déamination de la giutamine. Nous postulons que cette sequence
d'évènements peut étre Ia consequence d'une alteration de Ia
production d'alpha-cétoglutarate a partir du citrate.
Chronic metabolic acidosis dramatically increas-
es renal extraction and metabolism of glutamine in
many species [1]; the biochemical basis for this ad-
aptation, however, is incompletely understood. A
role for glutaminase induction seems unimportant
for a variety of reasons [2-4]. Likewise, a primary
role for regulation via enhanced renal gluconeogen-
esis is difficult to reconcile with studies of glucose
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turnover in dog kidneys in vivo [7, 8]. Two theories
of control are favored: there is an adaptive increase
in the transport of glutamine into renal mito-
chondria [9], or alternatively, there is a deinhibition
of glutaminase by reduced intramitochondrial gluta-
mate concentrations [10, 11]. A recent study on
phosphate-induced ammonia production in rabbits
[121 provides strong evidence for this latter con-
cept. In the present study, renal glutamine metabo-
lism in dogs was investigated in vivo following in-
fusions of fluorocitrate, a known inhibitor of citrate
aconitase [13]. The infusion of fluorocitrate into
dogs experiencing chronic metabolic alkalosis pro-
duced augmented extraction of glutamine, en-
hanced production of ammonia, and a significant
decrease in renal glutamate concentrations. These
values simulate those seen in chronic metabolic
acidosis. The significance of these results is dis-
cussed.
Methods
Experiments were performed on 23 female mon-
grel dogs, each weighing 15 to 23 kg. We induced
chronic metabolic alkalosis or acidosis by daily ad-
ministration for 5 days of 10 to 15 g of sodium bi-
carbonate or 10 g of ammonium chloride, respec-
tively, mixed with a standard laboratory diet. On
day 6, after being fasted overnight, the dogs were
anesthetized with pentobarbital (30 mg/kg of body
wt, i.v.). Small additional doses were given when
necessary. A midline abdominal incision was made
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to catheterize the left ureter proximal to its entry
into the bladder. Polyethylene catheters were in-
serted into the left femoral artery and vein through
an inguinal incision. A catheter filled with heparin-
saline was introduced into the inferior vena cava
from the right femoral vein, and its curved tip was
manipulated into the left renal vein. The left ovarian
vein was ligated. The right renal pedicle was then
ligated, and a piece of renal cortex immediately was
cut and dropped into liquid nitrogen. Elapsed time
from interruption of blood flow to freezing of tissue
was 10 to 15 sec.
The dogs were given fluids i.v. to achieve stable
urine flow rates during a 60-mm equilibration period
after closure of the abdomen. Acidotic dogs re-
ceived 145 m sodium chloride, and the alkalotic
ones received 72 m sodium chloride and 75 mrvt
sodium bicarbonate, at a rate of 3.5 mi/mm through-
out the experiment. After a priming dose of 1251-so-
dium iothalamate (Abbott Laboratories, Chicago)
was given, 0.5 sCiIkg was administered i.v. and
was followed by a sustaining dose of 0.0025 jCi X
GFRlmin (where single kidney GFR was estimated
to be 1.5 mI/kg/mm).
Four different experiments were carried out. In
the first group of eight dogs, the effects of sodium
DL-fluorocitrate were studied. Two control 20-mm
urine collections were obtained in which arterial
and renal venous blood samples were collected in
heparinized syringes. Then, a 145-mM sodium chlo-
ride solution containing sodium DL-fluorocitrate
was infused into an antecubital vein at 1.55 moles/
mm (0.76 mI/mm) for 80 mm. After a 20-mm equili-
bration period, three 20-mm urine collections were
made, with blood taken as was done in the control
period. After this, the abdomen was reopened
quickly and a piece of the left renal cortex was re-
moved and was frozen in liquid nitrogen. A similar
protocol was followed in a second group of six dogs
except that no fluorocitrate was infused. In a third
group of three dogs, the effects of sodium citrate on
renal ammonia production were determined. After
two 20-mm control periods, a priming dose of so-
dium citrate (14 mmoles in 50 ml H20, was infused
i.v. over 15 mm, followed by a sustaining dose of
170 tmo1es/min throughout the experiment. In a
fourth group of six dogs, the effects of fluorocitrate
on renal ammonia production during loading with a-
ketoglutarate were investigated. The protocol was
similar to the first group, except that after the two
control periods a priming dose of sodium a-keto-
glutarate (3.5 mmoles in 5 ml H20) was given i.v.,
followed by a sustained infusion of 90 prnoles/min
throughout the rest of the experiment. After 15 mm
of equilibration, two urine collections and blood
samples were taken as described above. The experi-
ments were continued then with the infusion of
fluorocitrate superadded. At the end of 80 mm, a
sample of tissue from the left kidney cortex was re-
moved and was frozen.
On the experimental day, urinary, arterial, and
renal venous ammonia concentrations were mea-
sured enzymatically by the method of Schmidt and
Schwarz [141, with the following modifications: (1)
blood samples were drawn immediately into 3-mi
pipettes, the blood then was mixed with 3 ml of ice-
cold 10% trichloracetic acid, and was centrifuged at
40 C; (2) deproteinized blood supernates were neu-
tralized with equal volumes of 0.125 M potassium
phosphate; (3) Tris buffer (0.5 M; pH, 7.6) was used
in the enzymatic assay. Plasma and urinary gluta-
mine [15], plasma, urine, and tissue citrate [161, tis-
sue glutamate [171, plasma and urinary a-keto-
glutarate [181 were determined enzymatically. DL-
fluorocitrate did not interfere with the citrate lyase
used in the citrate assay. All determinations were in
duplicate. Renal cortices were homogenized with a
Vir Tis homogenizer (Gardiner, N.Y.) in 0.6 M
perchloric acid.
We measured blood pH and Pco2 with a pH-gas
analyzer (Instrumentation Laboratory, Boston,
Mass.) and calculated plasma bicarbonate concen-
tration from the Henderson-Hassalbalch equation,
using a pK of 6. 10. Urinary pH was measured with
a pH meter (Radiometer, Copenhagen). 1251-iothala-
mate was counted in urine, arterial plasma and
blood, renal venous plasma and blood, and renal
cortical homogenate with an automatic gam-
macounter (Nuclear-Chicago, model 4216, Des
Plaines, Ill.). GFR was measured by iothalamate
clearance [191. Renal plasma and blood flows were
also measured with iothalamate with the Wolf [201
modification of the Fick principle. Total renal am-
monium production was calculated from the urinary
excretion plus the amount added to renal venous
blood. The renal uptake or utilization of glutamine,
citrate, and a-ketoglutarate was calculated in mi-
cromoles per minute, as follows:
RPF (Pa — Pry) + V(Prv — U)
where RPF is renal plasma flow, V is urine volume,
Pa is plasma arterial concentration, Pry is renal
venous plasma concentration, and U is urinary con-
centration of substrate.
Sodium DL-fluorocitrate was prepared from bari-
um DL-fluorocitrate (Calbiochem, Los Angeles) on
the day of the experiment. Barium DL-fluorocitrate
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Table 1. Effect of rm-fluorocitrate on renal hemodynamics and acid-base balance in dogs with chronic metabolic acidosis and chronic
metabolic alkalosis'
GFR RPF Urine
volume pH
.Arterial
bicarbonate
mnEqlliterArtery Renal vein Urine,nl/min
Acidotic dogs
Control 41.2 163.3 1.5 7.22 7.22 5.96 15.7
DL-Fluorocitrate infused 34.6 139.4 1.5 7.22 7.22 6.00 15.6
Alkalotic dogs
Control 33.0 129.3 1.2 7.51 7.50 8.02 32.8
OL-Fluorocitrate infused 31.5 99.8 1.4 7.52 7.51 7.96 34.7
a Values are mean 5EM in four acidotic dogs and four alkalotic dogs.
(225 mg) was dissolved in 145 m sodium chloride
(40 ml) containing sulfuric acid (1.65 mEq). Barium
sulphate was precipitated by centrifugation, and the
supernate was neutralized to a pH of 7.4 with 1 N
sodium hydroxide. The final volume was brought to
67 ml with distilled water.
Results are given as means SEM. Appropriate
statistical analyses were performed with either the
paired or unpaired Student's t test.
Results
Effects of DL-fluorocitrate. The administration of
ammonium chloride or sodium bicarbonate for 5
days induced a definite metabolic acidosis or alka-
losis, respectively (Table 1). A mean 11% decrease
in GFR and 18% decrease in RPF were observed
during the systemic infusion of fluorocitrate in these
animals. In a second group of control dogs (three
acidotic and three alkalotic) with the same protocol
except that fluorocitrate was omitted, there was no
change in GFR, but there was a mean 14% decrease
in RPF. Therefore, the decrease in GFR and possi-
bly part of the decrease in RPF could be attributed
to fluorocitrate. The infusion of fluorocitrate did not
affect the pH of urine or of arterial and renal venous
blood.
In view of the decrease in GFR with fluorocitrate,
the results were expressed per 100 ml of GFR. Total
ammonia production in the acidotic dogs was 3.5
times higher than it was in the alkalotic group under
control conditions (Table 2). Fluorocitrate adminis-
tration increased ammonia production significantly
by 23% in the acidotic dogs, with no change in arte-
rial blood ammonium concentrations. In chronic
metabolic alkalosis, ammonia production increased
by 340% compared to the control period. The extra
ammonia produced in alkalosis diffused into the
renal venous blood, where the pH was lower than it
was in the urine [211. A moderate but significant in-
crease in arterial blood ammonium was observed al-
so under these conditions.
Table 2. Effect of 1)L-fiuorocitrate infusion on renal ammonia production in dogs with chronic metabolic acidosis and chronic metabolic
a1kalosis'
Arterial blood NH3
noIe/m1
UrinaryNH3
NH3 added to
renal venous blood Total NH3 < 100GFR
pinoles/min/100 ml GFR
—
.uno1es/min
Acidotic dogs
Control 0.055 0.006 29.8 6.5 21.6 6.3 122.8 17.1
OL-Fluorocitrate infused 0.066 0.015 27.3 6.4 25.6 5.6 l5l.0' 11.7
Alkalotic dogs
Control 0.063 0.013 0.5 0.2 10.2 1.9 33.8 6.6
DL-Fluorocitrate infused Ø•888h 0.017 1.1 0.3 33.2k 5.2 ll0.6 17.0
a Values are mean 5EM in four acidotic dogs and four alkalotic dogs.
Value is significantly different from control value (paired analysis).
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Table 3. Effect of OL-fluorocitrate infusion on the renal uptake of glutamine in dogs with chronic metabolic acidosis and chronic
metabolic alkalosis
Glutamine
Arterial concentration
/JJnole/fnt
Extraction ratio
%
Renal uptake
pinoles/min/IOO ml GFR
Acidotic dogs
Control 0.450 0.038 38.0 5.1 66.8 5.9
DL-Fluorocitrate infused 0.394 0.022 43.9 5.2 76.5 6.6
Alkalotic dogs
Control 0.373 0.027 11.9 1.8 17.3 0.8
r)L-Fluorocitrate infused 0.387 0.032 48.3 I .6' 59.1 6.2'
Values are mean 5EM in four acidotic dogs and four alkalotic dogs.
Value is significantly different from control value (paired analysis).
In chronic metabolic acidosis, further increases
occurred in both the renal uptake of glutamine and
the glutamine extraction ratio (the percent of gluta-
mine load presented to the kidney that was extract-
ed) following fluorocitrate infusions (Table 3). Al-
though these increases are not statistically signifi-
cant (probably due to the small number of animals),
nonetheless, they correspond to the enhanced am-
moniagenesis referred to above. More strikingly,
the marked increase in glutamine utilization by the
kidneys during fluorocitrate infusions is highly sig-
nificant statistically in the chronically alkalotic
dogs. Interestingly, the renal extraction ratio of
glutamine in the alkalotic dogs receiving fluorocit-
rate is higher than that in the chronically acidotic
dogs. No glutamine was detected in the urine during
the control periods or during fluorocitrate infusion;
therefore, all glutamine extracted was metabolized
by the kidney.
Renal cortical glutamate concentrations were sig-
nificantly lower in acidotic compared to alkalotic
dogs (Table 4). Fluorocitrate significantly reduced
glutamate concentrations in both acidosis and alka-
losis. Glutamate also was significantly lower in al-
kalosis following fluorocitrate than that observed
during the control period in acidosis (P < 0.01).
To confirm that fluorocitrate actually inhibited
aconitase in kidneys, we determined tissue concen-
trations of citrate after 80 mm of infusion. In the
control state, citrate concentrations were observed
in both acid-base states. The described increase in
ammonium production was apparent after 20 mm of
fluorocitrate and reached a maximum 10 to 20 mm
later. In two additional alkalotic dogs, the experi-
mental kidney was frozen at the end of only 30 mm
of infusion. The mean renal cortical glutamate and
citrate concentrations were 4.9 and 3.6 Lmoles!g of
wet tissue, respectively, close to the values ob-
served after 80 mm.
To exclude unknown factors other than fluorocit-
rate, which might have influenced the results, we
studied a separate group of six dogs in the same
manner. The mean total renal ammonia production
was stable during the five 20-mm urine collection
periods, both in acidosis and alkalosis. The values
obtained were very similar to those of the control
periods of the experiments referred to above. Iden-
tical patterns were also observed in relation to
glutamine uptake and to tissue concentrations of
glutamate and citrate. Thus, we conclude that the
results obtained are due to fluorocitrate administra-
tion.
Effects of citrate infusion. Because tissue con-
centrations of citrate increased when aconitase was
inhibited, we investigated whether a primary in-
crease in intracellular concentrations of this tn-
carboxylic acid might influence glutamine metabo-
Table 4. Effect of DL-fluorocitrate on the renal cortical concen-
tration of citrate and glutamate in dogs with chronic metabolic
acidosis and chronic metabolic alkalosisu
Glutamate Citrate
p.mole/g wet tissue
Acidotic dogs
Control 5.2 0.2 0.10 0.01
oLFluorocitrate infused 3.5 0.2' 4.17 0.40'
Alkalotic dogs
Control 9.4 0.4 0.16 0.02
DL-Fluorocitrate infused 3.8 0.2' 5.33 0.50'
Values are mean 5EM in four acidotic dogs and four alka-
lotic dogs.
Value is significantly different from control value (paired
analysis).
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TableS. Effect of OL-fluorocitrate on renal ammonia production during a-ketoglutarate infusion in dogs with chronic metabolic acidosis
and chronic metabolic alkalosis"
GFR RPF
—-——---—
mi/mm
Ammonia Glutamine
production uptake
——
a- Ketoglutarate
Renal cortex
Arterial
plasma
pinole/mI
Renal
uptake
pmoles/minl
/00 ml GFR
Glutamate Citrate
—
pmoles/g wet tissueimoles/minIl00 ml GFR
Acidotic dogs
Control 33.6 125.0 139.7 62.4 0.01
—
—
—.
5.22 0.10
a-Ketoglutarate infused 17.9 — —
a-Ketoglutarate 37.1 102.6 148.1 56.7 0.29 61.6 4.63 ÷615"
+ DL-fiuorocitrate infused 18.5 10.0
Alkalotic dogs
Control 35.7 147.9 24.5 19.3 0.01
—
—
—
9.82 0.13
a-Ketoglutarate infused 36.4 125.0 22.8 16.5 0.23 55.8 — —
— —
a-Ketoglutarate 31.8 100.2 51.7" 36.7' 0.21 53.2 4.84" 5.54"
+DL-fiuorocitrate infused ±6.2 ±12.4 ±7.9 ±7.9 ±0.05 ±7.3 ±0.38 ±1.12
Values are mean ± SEM in two acidotic dogs and in four alkalotic dogs.
"Value is significantly different from the control value (paired analysis).
lism in vivo. We infused sodium citrate into three
dogs with chronic metabolic alkalosis. We used the
largest amounts that the dogs could tolerate without
developing arrhythmias or other untoward clinical
signs (see 'Methods"). After we infused citrate for
25 mm, plasma citrate stabilized at concentrations
20 times higher (3.09 rm/ml) than did the endoge-
nous concentrations (0.17 jsm!ml). Tubular citrate
reabsorption increased moderately, renal utilization
of citrate rose substantially (25.7 vs. 5.9 1Lm/min),
and the renal cortical concentrations of citrate were
as high as that observed during fluorocitrate in-
fusion (4.11 vs. 0.20 sm/g of wet weight). Despite
this, total ammonia production did not increase dur-
ing the three 20-mm periods of observation (25.8 vs.
26.5 sm/min). Although under these experimental
conditions, net tubular citrate reabsorption ex-
ceeded control, total filtered citrate was poorly
reabsorbed (citrate clearance/GFR = 0.91). To esti-
mate the distribution of the citrate under these con-
ditions, we determined the concentrations of l2J..
iothalamate in kidney homogenates and plasma in
the following way: In a group of ten alkalotic dogs
treated in a manner similar to the last experiments,
the ratio of the simultaneous concentrations of '"I-
iothalamate in I g (wet weight) of renal cortex to
that of 1 ml of plasma was 1.44 ± 0.04 (unpublished
observations). If one assumes citrate and iothala-
mate to be handled in a relatively similar manner, a
renal cortical concentration of 4.3 tmoles/g wet
weight would be predicted, with a plasma citrate
concentration of 3 tmoles/ml (the mean value de-
termined in the three dogs). This is close to the con-
centration actually observed (4.1 jsm/g of wet
weight), suggesting that most of the citrate brought
to the kidney in the circulation may be actually in
extracellular space.
Effect of fluorocitrate during infusion of a-keto-
glutarate. After being infused with a-ketoglutarate
(see 'Methods"), four chronically alkalotic dogs
had a mean plasma a-ketoglutarate concentration of
0.23 smole/mt, and two chronically metabolic aci-
dotic dogs had a mean value of 0.29 rmole/ml (Table
5). Their mean renal uptake of a-ketoglutarate was
55.8 and 73.8 zmoles/minI100 ml GFR, respective-
ly. During infusion, their total renal ammonia pro-
duction decreased by about 10% compared to the
control period in both groups, but this change was
not significant statistically. Fluorocitrate infusion
was begun 55 mm after starting the ct-ketoglutarate
infusion, and both were continued simultaneously.
During this latter period, arterial plasma a-keto-
glutarate concentration did not alter. Renal clear-
ance decreased, although not significantly, from
14.9% to 8.5% of GFR in the alkalotic dogs. The
renal uptake of a-ketoglutarate was not altered by
fluorocitrate in either acidosis or alkalosis. The
mean extraction ratio of et-ketoglutarate was 0.86
prior to fluorocitrate administration and was not dif-
ferent during infusion of the inhibitor. The aconi-
tase was inhibited, as inferred from the striking rise
in tissue citrate. At the same time, total renal am-
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Table 6. Effect of OL-fluorocitrate and of s-ketoglutarate + ui-fiuorocitrate infusions on renal ammonia production and renal cortical
concentrations of glutamate and citrate in dogs in chronic metabolic acidosis and chronic metabolic alkalosis"
Renal cortex
.Ammonia production
grnoles/;riin/IOO nil GFR
Glutamate
—____________________
Citrate
,.iinoles/g Wet (iOue
Acidotic dogs
Control 119.2 11.1 4.55 0.34 0.12 0.03
uL-Fluorocitrate 151.0 11.7 3.46 0.18' 4.17 0.40'
cs-Ketoglutarate + 148.1 10.0 4.63 0.69e 6.15 2.83
Di. -fluorocitrate
Alkalotic dogs
Control 26.1 3.8 8.58 0.10 0.39 0.10
DL-fiuorocitrate 110.6 17.0' 3.80 0.19" 5.33 0.50'
a-Ketoglutarate+ 51.7 7.9' 4.84 0.38' 5.54 1.12'
DL-fluorocitrate
Values are mean SEM in six control dogs (three acidotic and three alkalotic), eights dogs with DL-fluorocitrate infusion (four
acidotic and four alkalotic), and six dogs with a-ketoglutarate + DL-fiuorocitrate infusion (two acidotic and four alkalotic).
Value is significantly different from control value (group analysis).
Value is significantly different from i)L-fiuorocitrate value (group analysis).
monia production approximately doubled over the
control period in alkalosis; no significant change
was observed in acidosis. The changes in glutamine
uptake were commensurate with the increase in am-
monia production under these conditions, and
glutamate concentration decreased in the renal cor-
tex.
To present a clearer picture of the influence of
superadded a-ketoglutarate administration on the
effects produced by fluorocitrate, we summarize
data from three groups of dogs in Table 6: (a) the six
control dogs who received no infusion, (b) the eight
dogs infused with fluorocitrate alone, and (c) the six
dogs infused with a-ketoglutarate and fluorocitrate.
ct-Ketoglutarate infusion did not alter the rise in
renal cortical citrate concentrations induced by
Iluorocitrate administration alone. Tissue glutamate
concentrations were significantly higher during the
combined administration of ct-ketoglutarate and
fluorocitrate than they were during fluorocitrate ad-
ministration alone. Although total renal ammonia
production during combined ct-ketoglutarate and
fluorocitrate infusion in alkalosis is approximately
twice the control value, it is on the other hand
less than half that observed during infusion of the
inhibitor alone. At the dose of a-ketoglutarate
used, no changes in ammonia production were
observed in acidosis when both compounds were
administered compared to when fluorocitrate was
administered alone. The small number of experi-
ments, however, does not allow a definitive con-
clusion.
Discussion
Inhibitors of substrate oxidation have been used
to study the regulation of renal ammonia production
[22]. Under certain circumstances, arsenite [23], io-
doacetate [24, 25], 4-pentanoic acid [26], maleate
[24], malonate [II, 24, 27, 281, and fluorocitrate
(fluoroacetate) [12, 281 augment ammoniagenesis by
rat and dog renal tissue in vivo and in vitro.
Fluorocitrate and fluoroacetate, which metabo-
lizes to fluorocitrate, are interesting inhibitors. Al-
though they may decrease succinic dehydrogenase
activity [291, their primary site of inhibition is on the
citrate aconitase pathway [13, 28, 291—the result,
citrate accumulation. In vitro, these inhibitors en-
hance rat renal slice ammoniagenesis from gluta-
mate [281 and enhance glutamine ammonia produc-
tion in mitochrondria from rats and rabbits [12]. In
vivo, fluorocitrate acutely augments renal ammo-
nium excretion by rats [281. In the present studies,
there was a 20- to 40-fold rise in renal cortical cit-
rate concentrations within 80 mm following infusion
of the aconitase inhibitor fluorocitrate. This oc-
curred in both chronically acidotic and alkalotic
dogs (Table 4). Similar values were observed also in
two dogs at 30 mm. Apart from an 11% fall in GFR
(Table 1), no other significant effects of fluorocitrate
were obvious, and no changes in blood pressure,
blood gases, or pH occurred. Despite this, renal
ammoniagenesis and glutamine extraction rose sig-
nificantly in alkalotic dogs. The rise in total renal
ammonia production was evident within 20 mm of
infusion, reached its maximum within 40 mm, and
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was maintained throughout the experiment (Tables
2 and 3).
All increase in ammoniagenesis could be ex-
plained by glutamine metabolism because for every
2 moles of ammonia produced, the kidney extract-
ed approximately 1 smole of glutamine from the cir-
culation. Of major interest to us, the extraction and
uptake of glutamine and its metabolism to ammonia
in alkalotic dogs receiving fluoroacetate for only 40
mm was of the same order as that achieved in dogs
after 5 days of ammonium chloride administration.
In our acidotic dogs, a smaller but significant 23%
increase in the production of ammonia followed
fluorocitrate administration. The duration of these
experiments was sufficiently short to make any
change in enzyme synthesis or degradation most
unlikely [301.
The reduced cortical glutamate concentrations
previously reported in chronic metabolic acidosis
compared to the normal and alkalotic states were
confirmed [31]. Fluorocitrate induced a further sig-
nificant fall in glutamate concentrations in acidotic
dogs and a more dramatic fall in the alkalotic group
(Table 4). These changes were evident within 30
mm in two dogs. Thus, renal glutamate concentra-
tions were decreased by fluorocitrate despite in-
creased deamidation of glutamine.
Could elevated renal citrate concentrations be re-
sponsible for our results? Filtered citrate is reab-
sorbed by the tubules, but citrate is extracted by the
kidneys in amounts even larger than that filtered
[32]. We could only conclude that citrate enters the
tubular cells through both luminal and anteluminal
membranes [32], and that we could increase intra-
cellular citrate in the tubular cells by augmenting
plasma citrate concentrations seemed feasible. Fol-
lowing sodium citrate infusions that produced cor-
tical citrate concentrations similar to those obtained
following fluorocitrate infusions, renal ammonia-
genesis was unaltered. The indirect studies on tis-
sue citrate distribution (see "Results") are compat-
ible, however, with most of the citrate being ex-
tracellular rather than intracellular in our experi-
ments. Caution is necessary, therefore, in inter-
preting these results. Other studies have shown,
however, that citrate itself decreases renal ammo-
niagenesis in vivo and in vitro 123, 33], and of
course, renal citrate concentrations are low in acid-
osis [34]. That the increasing concentrations of cit-
rate are directly responsible for augmented ammo-
niagenesis here seems unlikely.
Could the lower tissue concentrations of gluta-
mate contribute to adapted renal ammoniagenesis?
A biochemical association between glutamate re-
moval and glutamine deamidation has been made
[11]. The temporal relationship between adapted
ammonia production and the decrease in tissue
glutamate concentrations suggests an association.
More strikingly, the concomitant administration of
both a-ketoglutarate and fluorocitrate significantly
reduced the increase in ammoniagenesis and the de-
crease in the cortical glutamate observed with the
aconitase inhibitor alone (Table 6). We conclude,
like others [351, that the elevations in tissue gluta-
mate secondary to a-ketoglutarate infusions are re-
sponsible for the lowering of renal ammoniagenesis.
These results suggest strongly that fluorocitrate
has increased renal ammoniagenesis through its
ability to lower tissue glutamate concentrations and
to deinhibit secondarily phosphate-dependent glu-
taminase [10, 11]. One might argue, however, that
such events must take place intramitochondrially
and that we are measuring whole cortical glutamate
concentrations. The question then becomes wheth-
er tissue glutamate concentrations reflect mitochon-
drial concentrations. Our opinion is that they do.
The 2:1 ratio of ammonia produced to glutamine ex-
tracted during fluorocitrate infusions indicates that
both nitrogens of glutamine are used to form am-
monia. In unreported observations, we have seen
that enhancing the intramitochondrial deamination
of glutamine by infusing this amino acid into alka-
lotic dogs can increase ammonia production to lev-
els seen in acidosis, but the above ratio remains
closer to I than it does to 2 (Lombardo et al, unpub-
lished observations). These findings coupled with
others derived from in vitro studies using fluorocit-
rate or fluoroacetate [12, 28] shift the burden of
proof on those proposing that decreases in tissue
glutamate following fluorocitrate infusions do not
reflect augmented intramitochondrial deamination
of the amino N portion of glutamine.
Although it seems likely that changes in tissue
glutamate concentrations reflect mitochondrial lev-
els and directly regulate ammoniagenesis in our
studies, the events creating the more rapid removal
of glutamate are less clear. Two possibilities have
been proposed. Recently, Yu et al [121 demon-
strated a markedly enhanced ammoniagenesis in
rabbit slices and mitochondria by the addition of
phosphate. Phosphate infusions also increased am-
monium excretion in rabbits. They concluded that
phosphate-induced ammoniagenesis resulted from
increased mitochrondrial malate exit through phos-
phate exchange via the mitochondrial dicarboxylate
carrier. This would lead to decreased intra-
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mitochondrial concentrations of malate and its pre-
cursors, thereby favoring enhanced deamination of
glutamate to a-ketoglutarate. That phosphate had a
similar effect when glutamate rather than glutamine
was used as a substrate further strengthens this hy-
pothesis. Additionally, when they added fluoroace-
tate (metabolic precursor to fluorocitrate [13]) to
mitochondria, enhanced ammoniagenesis was ob-
served once more [121. They postulated the follow-
ing schema. Accumulation of citrate within mito-
chondria. fascilitated malate exit from the mito-
chondria via the citrate-malate exchanger. By
virtue of fluoroacetate's inhibition of citrate con-
version to a-ketoglutarate and the faster exit of mal-
ate, concentrations of a-ketoglutarate within mito-
chondria decrease. The disappearance of the end
product of glutamate deamination would cause even
more glutamate removal.
Preuss and Weiss proposed another hypothesis
[24]. They developed a working model, based on
earlier reports of Krebs [36] and Haslam [37] where
substrates compete for a common pool of oxidized
pyridine nucleotides [24, 27]. Reducing the oxida-
tion of substrates such as citrate [28] and cs-keto-
glutarate [23], either by inhibiting their oxidative
decarboxylation [23, 24] or by removing them from
oxidative sites within mitochondria [121, could free
more oxidized pyridine nucleotides for glutamate
deamination. Favoring this concept is the finding
that in vitro inhibition of glutamate deamination by
the addition of a-ketoglutarate can be overcome by
arsenite despite the continued presence of supra-
normal concentrations of z-ketoglutarate [24].
Fluorocitrate infusions into dogs elevate renal cit-
rate concentrations. There is no doubt that this
agent blocks aconitase activity. Fluorocitrate, how-
ever, can also block succinic dehydrogenase activi-
ty [29] and perhaps other enzymes as well. In rat
renal slices, there is no evidence for the latter ac-
tion, as the addition of fluorocitrate to incubating
kidney slices does not inhibit gluconeogenesis from
glutamate as does malonate, a well-described inhib-
itor of succinic dehydrogenase [28]. In contrast,
fluorocitrate inhibits gluconeogenesis from citrate
[281.
Although we believe the major effect of fluorocit-
rate to be through its blocking the activity of aconi-
tase, the blocking of the activity of succinic dehy-
drogenase or, for that matter, of other pathways of
metabolism could still lead to enhanced renal am-
moniagenesis. Malonate, the best studied of the
metabolic inhibitors given to rats in vivo, raises tis-
sue concentrations of succinate [38], decreases re-
nal concentrations of glutamate [27], and augments
renal ammonium excretion [28]. In isolated tubules
of dogs, malonate enhances the deamination of
glutamate formed as glutamine is deamidated [281—
the result, faster glutamate removal. Malonate
could create faster glutamate removal because it
stimulates a-ketoglutarate removal from mito-
chondria [12], or inhibits tricarboxylic acid cycle
activity [24], or both.
Summary. We propose the following schema
based on our results. Fluorocitrate infusions inhibit
the tricarboxylic acid cycle principally at the citrate
aconitase step. By virtue of this inhibitory effect,
intermediates distal to citrate would be expected to
fall. The lower intramitochondrial concentrations of
a-ketoglutarate, or decreased tricarboxylic acid
cycle activity, or both lead to decreased glutamate
concentrations through faster deamination. Such a
reduction in intramitochondrial glutamate concen-
trations would increase glutamine deamidation be-
cause of deinhibition of glutaminase. Because
fluorocitrate increases renal ammoniagenesis to the
same magnitude as does adaptation to persistent
acid challenge, these results suggest that implemen-
tation of glutamate removal via deamination could
account potentially for all the adaptation of ammo-
niagenesis during chronic acidosis. Last, the ap-
proximately 2:1 ratio between ammonia production
and glutamine utilization observed in alkalosis fol-
lowing fluorocitrate supports the hypothesis that all
the increase in ammonia is derived from the com-
plete conversion of glutamine to cx-ketoglutarate via
the intramitochondrial glutaminase pathway rather
than the extramitochondrial glutamine amino-
transferase w-amidase pathway.
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